In this article, we review seminal articles that have evaluated the molecular architecture of pancreatic cancer. We compare the methods used and the molecular subtypes defined, and assess the predominant subgroups in order to better understand which therapies may improve patient outcomes.
The onset of diabetes or the rapid deterioration of existing diabetes may be an early signal for pancreatic cancer for some patients, according to the results of a study presented at the European Cancer Congress.
These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.
Annual screening of people at high risk for pancreatic ductal adenocarcinoma (PDAC) because of CDKN2A mutations was relatively successful and allowed for the detection of disease in time to perform surgery.